11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood

Constitutional or somatic mosaic epimutations are increasingly recognized as a mechanism of gene dysregulation resulting in cancer susceptibility. Beckwith‐Wiedemann syndrome is the cancer predisposition syndrome most commonly associated with epimutation and is extremely variable in its phenotypic presentation, which can include isolated tumors. Because to the authors' knowledge large‐scale germline DNA sequencing studies have not included methylation analysis, the percentage of pediatric cancer predisposition that is due to epimutations is unknown.

[1]  A. Koç,et al.  The Efficiency of SNP-Based Microarrays in the Detection of Copy-Neutral Events at 15q11.2 and 11p15.5 Loci , 2019, Journal of Pediatric Genetics.

[2]  A. Ganguly,et al.  Molecular diagnosis of somatic overgrowth conditions: A single‐center experience , 2019, Molecular genetics & genomic medicine.

[3]  T. Hadjistilianou,et al.  Evidence of predisposing epimutation in retinoblastoma , 2018, Human mutation.

[4]  J. Kalish,et al.  Defining an optimal time window to screen for hepatoblastoma in children with Beckwith‐Wiedemann syndrome , 2018, Pediatric blood & cancer.

[5]  Xiaotu Ma,et al.  Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome , 2018, Nature Communications.

[6]  A. Ganguly,et al.  Diagnosis of Beckwith–Wiedemann syndrome in children presenting with Wilms tumor , 2018, Pediatric blood & cancer.

[7]  R. Hennekam,et al.  Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement , 2018, Nature Reviews Endocrinology.

[8]  K. Pritchard-Jones,et al.  Bilateral Wilms tumour: a review of clinical and molecular features , 2017, Expert Reviews in Molecular Medicine.

[9]  T. Druley,et al.  Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma , 2017, Clinical Cancer Research.

[10]  S. Fröhling,et al.  FUS–DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma , 2017, Clinical Cancer Research.

[11]  Saskia M. J. Hopman,et al.  Phenotype, cancer risk, and surveillance in Beckwith–Wiedemann syndrome depending on molecular genetic subgroups , 2016, American journal of medical genetics. Part A.

[12]  G. Ferrero,et al.  Cancer Risk in Beckwith-Wiedemann Syndrome: A Systematic Review and Meta-Analysis Outlining a Novel (Epi)Genotype Specific Histotype Targeted Screening Protocol. , 2016, The Journal of pediatrics.

[13]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[14]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[15]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[16]  P. Meltzer,et al.  Recurrent epimutation of SDHC in gastrointestinal stromal tumors , 2014, Science Translational Medicine.

[17]  Erin K. Hedlund,et al.  Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project , 2014 .

[18]  S. Walther,et al.  Prenatal diagnosis in haemophilia A: experience of the genetic diagnostic laboratory , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  P. Radice,et al.  The IGF signalling pathway in Wilms tumours - A report from the ENCCA Renal Tumours Biology-driven drug development workshop , 2014, Oncotarget.

[20]  M. Vazquez,et al.  Beckwith-Wiedemann Syndrome: Growth Pattern and Tumor Risk according to Molecular Mechanism, and Guidelines for Tumor Surveillance , 2013, Hormone Research in Paediatrics.

[21]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[22]  T. Haaf,et al.  Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer , 2012, Human molecular genetics.

[23]  L. Helman,et al.  Targeting the insulin growth factor receptor 1. , 2012, Hematology/oncology clinics of North America.

[24]  Li Ding,et al.  The Pediatric Cancer Genome Project , 2012, Nature Genetics.

[25]  M. Szyf.  DNA methylation signatures for breast cancer classification and prognosis , 2012, Genome Medicine.

[26]  Nazneen Rahman,et al.  Stratification of Wilms tumor by genetic and epigenetic analysis , 2012, Oncotarget.

[27]  C. Gicquel,et al.  Allele‐specific methylated multiplex real‐time quantitative PCR (ASMM RTQ‐PCR), a powerful method for diagnosing loss of imprinting of the 11p15 region in Russell Silver and Beckwith Wiedemann syndromes , 2011, Human mutation.

[28]  N. Rahman,et al.  Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor , 2008, Nature Genetics.

[29]  M. Ebert,et al.  Further evidence for heritability of an epimutation in one of 12 cases with MLH1 promoter methylation in blood cells clinically displaying HNPCC , 2008, European Journal of Human Genetics.

[30]  S. Ogawa,et al.  Whole‐genome profiling of chromosomal aberrations in hepatoblastoma using high‐density single‐nucleotide polymorphism genotyping microarrays , 2008, Cancer science.

[31]  David I. K. Martin,et al.  Inheritance of a cancer-associated MLH1 germ-line epimutation. , 2007, The New England journal of medicine.

[32]  S. Warren,et al.  Molecular diagnosis of Beckwith-Wiedemann Syndrome using quantitative methylation-sensitive polymerase chain reaction , 2006, Genetics in Medicine.

[33]  S. Leung,et al.  Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer , 2006, Nature Genetics.

[34]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[35]  D. Higgs,et al.  Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease , 2003, Nature Genetics.

[36]  R. Weksberg,et al.  Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations. , 2001, Genomics.

[37]  H. Hoyme,et al.  Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. , 1998, American journal of medical genetics.

[38]  A. Feinberg,et al.  Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. , 1997, American journal of human genetics.

[39]  D. Barton,et al.  Mosaic uniparental disomy in Beckwith-Wiedemann syndrome. , 1994, Journal of medical genetics.

[40]  R. Weksberg,et al.  Disruption of insulin–like growth factor 2 imprinting in Beckwith–Wiedemann syndrome , 1993, Nature genetics.

[41]  L. Strong,et al.  Genetic mosaicism in normal tissues of Wilms' tumour patients , 1993, Nature Genetics.

[42]  Nan Faion T. Wu,et al.  The Beckwith-Wiedemann Syndrome , 1974, Clinical pediatrics.

[43]  N Breslow,et al.  Epidemiology of Wilms tumor. , 1993, Medical and pediatric oncology.